UK markets closed
NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,207.13 +444.10 (+2.50%) CRUDE OIL
79.16 +0.21 (+0.27%) GOLD FUTURES
2,314.50 +4.90 (+0.21%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
47,316.52 +1,210.96 (+2.63%)
BioInvent International AB (publ) (0H22.IL)
IOB - IOB Delayed price. Currency in SEK
Add to watchlist
At close: 05:15PM BST
| Previous close | 25.15 |
| Open | 0.00 |
| Bid | 25.35 x N/A |
| Ask | 28.00 x N/A |
| Day's range | 21.50 - 21.50 |
| 52-week range | 14.35 - 28.30 |
| Volume | |
| Avg. volume | 40 |
| Market cap | 1.877B |
| Beta (5Y monthly) | 0.28 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.01 |
| Earnings date | 24 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireCASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, and BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced preliminary encouraging efficacy data for BI-1206 in combination with rituximab in patients
© 2024 Yahoo. All rights reserved.